Navigation Links
Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
Date:7/20/2009

f its first quarter revenue from non-traditional pharmaceutical businesses.

Mr. Poussot said the Company's solid performance was driven by continued growth in its core franchises, Enbrel, Prevnar and Nutritionals, and increased contribution from its newer products, Tygacil, Torisel, Pristiq and Relistor. This solid growth is helping to offset the expected declines of products with emerging generic competition. The Company will report its second quarter financial results on July 23, 2009.

In other business, Wyeth stockholders re-elected 11 current members of the Company's Board of Directors. Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2009.

In addition, Wyeth stockholders rejected a stockholder proposal regarding reporting on the Company's political contributions and trade association payments; and approved a stockholder proposal requesting the Board to adopt an amendment to Wyeth's bylaws to give holders of 10% of outstanding common stock the power to call special shareowner meetings. The votes on these two stockholder proposals were tabulated in the event the merger does not close and Wyeth continues as a publicly traded company.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from thos
'/>"/>

SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
2. Wyeth Announces Holder Right to Surrender Convertible Debentures
3. Wyeth Declares Common Stock Dividend
4. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
5. Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
6. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
7. Wyeth Declares Common and Preferred Stock Dividends
8. Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings
9. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
10. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
11. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 Oxford Finance LLC ... to life sciences and healthcare services companies, today announced ... loan agreement with Celula, Inc., a diagnostic testing company ... enabling better patient care and improved outcomes.  Proceeds of ... and expand the commercialization of its products in the ...
(Date:4/30/2015)... 30, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... of biosimilar therapeutics including high value and difficult ... its previously announced underwritten public offering of 6,750,000 ... offering price of $15.50 per share. This includes ... their option to purchase up to 750,000 additional ...
(Date:4/30/2015)... April 30, 2015 Available in ... http://www.lespausa.com , Fleur’s introduces ... combining the benefits of makeup, skin care and ... tinted cream is designed with specific complexion-correcting pigments ... even complexion and a healthy glow. Far more ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Sterlitech ... ultrafiltration membranes, the PX, PY, and PZ ... sheets, and disks. Designed to be ideal ... new membranes can fill critical process requirements where ... downstream processes. , “New regulations on industrial wastewater ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Sterlitech Offers New Ultrafiltration Membranes 2
... to $33.2 Million, ... $12.8 Million, -- The Company Provides ... NEW YORK and HAIKOU, Hainan, China, March 31,/Xinhua-PRNewswire-FirstCall/ -- ... which develops, manufactures, and,markets generic and branded bio-pharmaceutical products ...
... on Lead Compounds That Directly and Specifically Activate ... ... Massachusetts, March 31 Mercury Therapeutics,Inc. (MTI), a company that discovers ... filed for patent protection on,three lead compounds that directly and specifically ...
... Vaccine Technology and ... Bird Flu Clinical Program, Webcast/teleconference Call Set ... March 31 Carrington,Laboratories, Inc. (OTC Bulletin Board: CARN) today reported ... ($0.90) per basic and,diluted share, for the year ended December 31, ...
Cached Biology Technology:China Pharma Holdings, Inc. Announces Record 2007 Year End Results 2China Pharma Holdings, Inc. Announces Record 2007 Year End Results 3China Pharma Holdings, Inc. Announces Record 2007 Year End Results 4China Pharma Holdings, Inc. Announces Record 2007 Year End Results 5China Pharma Holdings, Inc. Announces Record 2007 Year End Results 6China Pharma Holdings, Inc. Announces Record 2007 Year End Results 7China Pharma Holdings, Inc. Announces Record 2007 Year End Results 8China Pharma Holdings, Inc. Announces Record 2007 Year End Results 9China Pharma Holdings, Inc. Announces Record 2007 Year End Results 10China Pharma Holdings, Inc. Announces Record 2007 Year End Results 11Mercury Therapeutics Patents Filed 2Mercury Therapeutics Patents Filed 3Carrington Reports 2007 Financial Results 2Carrington Reports 2007 Financial Results 3Carrington Reports 2007 Financial Results 4Carrington Reports 2007 Financial Results 5Carrington Reports 2007 Financial Results 6Carrington Reports 2007 Financial Results 7
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ... "India Sensors Market Forecast and Opportunities 2020" ... market is projected to grow at a CAGR ... automotive, industrial and healthcare sectors are the key ... addition, adoption of MEMS technology in sensors is ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... . . . ,Researchers at the Bio-SANS instrument ... and small-angle neutron scattering to get a first insight ... complexes. The unique properties of polyelectrolyte materials are of ... membrane -- three-dimensional bio-scaffolds to grow cells for regenerating ...
... of Medicine, Hershey, Pennsylvania have discovered that the presence ... which mediates the inhibitory action of opioid growth factor ... the progression and treatment of human ovarian cancer. ... engineered to have a reduced expression of OGFr, into ...
... threats to tropical coral reefs can be a population outbreak ... can consume live corals over large areas, a change that ... the aesthetic value of coral reefs, which in turn negatively ... triggers and spread of COT outbreaks are not fully understood. ...
Cached Biology News:Feb. 21, 2012, story tips 2Feb. 21, 2012, story tips 3A breakthrough in understanding the biology and treatment of ovarian cancer 2A breakthrough in understanding the biology and treatment of ovarian cancer 3Coral-eating sea star invaders turn out to be locals 2
... making flow cytometry accessible to anyone in the ... latest addition to Guavas on-demand microcapillary flow cytometry ... to use, surprisingly affordable, very compact, and nicely ... The Guava EasyCyte Mini has all of the ...
... unique combination of Coulter volume and ... and accurate cell counting. This flow ... UV, allowing flexible fluorochrome selection for ... only achievable with larger, more expensive ...
... crosslinked to protein G-agarose beads which can ... heart mitochondria. Also included are 2 mg ... ,The pyruvate dehydrogenase complex (PDH) immunocapture kit ... of tissue. This facilitates the subsequent analysis ...
... Protein/antibody delivery using PULSin may be superior ... example, unlike traditional transfection, with PULSin you ... level and time course of proteins in ... provide more information than traditional RNA interference ...
Biology Products: